Drug Trial Radar · NCT07748039
Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,440
Planned (sponsor's estimate)
Start
Oct 16, 2026
Primary completion
Mar 1, 2029
Study completion Aug 1, 2029
Sponsor
- Lead sponsor
- Yongjun WangAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Acute ischemic stroke caused by large vessel occlusion (LVO) is a major cause of disability, and mechanical thrombectomy (MT) has become the standard treatment for eligible patients. However, the optimal role of intravenous thrombolysis before MT remains uncertain. The TRACE-BRIDGE trial is a phase 3, investigator-initiated, multicenter, randomized, open-label trial with blinded outcome assessment (PROBE design) evaluating different bridging thrombolysis strategies before MT. The trial will enroll adults with acute ischemic stroke presenting within 4.5 hours of symptom onset and with imaging-confirmed anterior circulation LVO who are eligible for intravenous thrombolysis and MT. Participants will be randomly assigned in a 1:1:1 ratio to receive tenecteplase plus MT, reteplase plus MT, or direct MT alone. The TRACE-BRIDGE trial aims to evaluate the efficacy and safety of bridging thrombolysis with tenecteplase or reteplase before mechanical thrombectomy compared with direct mechanical thrombectomy. The primary outcome is functional independence, defined as a modified Rankin Scale score of 0-2 at 90 days after randomization. If superiority of bridging thrombolysis is demonstrated, the trial will further evaluate whether reteplase is non-inferior to tenecteplase as a bridging thrombolytic strategy.
Conditions
- Acute Ischemic Stroke
- Large Vessel Occlusion
- Anterior Circulation Brain Infarction
Interventions
rhTNK-tPA (0.25mg/kg)Drug
Recombinant human TNK tissue-type plasminogen activator (rhTNK-tPA) administered as a single intravenous bolus at a dose of 0.25 mg/kg (maximum dose 25 mg) within 4.5 hours of symptom onset prior to mechanical thrombectomy.
Reteplase 10 Units (U) plus a second dose of reteplase 10 UDrug
Two intravenous bolus injections of 18 mg each, administered within 4.5 hours of onset over approximately 2 minutes per bolus, separated by a 30-minute interval prior to thrombectomy. To avoid delays in reperfusion therapy, groin puncture and MT procedures may be initiated after administration of the first 18 mg bolus, without waiting for completion of the second bolus. Unless contraindicated, the second rPA bolus should be administered according to the scheduled dosing regimen irrespective of EVT status.
No thrombolysis (thrombectomy alone)Procedure
Patients will undergo mechanical thrombectomy according to standard practice, without administration of intravenous thrombolytic agents.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Functional IndependenceTime frame: From randomization to 90 days after randomization (±7 days), with outcome assessment performed by blinded assessors.
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Beijing Tiantan Hospital, Capital Medical Universiity
Beijing, Beijing Municipality, China · Recruiting
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China · Not yet recruiting
Xiangtan Central Hospital
Xiangtan, Hunan, China · Not yet recruiting
Rizhao Hospital of Traditional Chinese Medicine
Rizhao, Shandong, China · Not yet recruiting
Ya'an People's Hospital
Ya'an, Sichuan, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.